ArticleMolecular therapy. Nucleic acids2023
Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using
Article in Molecular therapy. Nucleic acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 51 citations in OpenAlex.
- Emerging strategies and innovations in circular RNA synthesis.Molecular therapy. Nucleic acids · 2026Review
- Target site selection and P1 engineering enable highly efficient circular RNA production via end-to-end self-targeting and splicing.Nucleic acids research · 2026Article
- Split intron-exon system for circular RNA synthesis.Nature communications · 2026Article
- Review
- Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer.Nature biomedical engineering · 2026Article
- Generation of precise and accurate engineered circRNAs using enzymatic ligation.Nucleic acids research · 2026Article
- Delivery of Circular RNAs into Splenic Immune Cells via Intravenous Administration of Polyaspartamide Derivative Polyplexes.ACS biomaterials science & engineering · 2026Article
- "More" Artificial mRNAs: Beyond the Art of Nature.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives.Vaccines · 2026Review
- Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases.Frontiers in immunology · 2026Review
- Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy.Signal transduction and targeted therapy · 2025Article
- Molecular basis of backsplicing regulation and its application to manipulate circRNA levels.RNA biology · 2025Review
- RNA denaturation underlies circular RNA separation.Nucleic acids research · 2025Article
- Exploring the frontier of non-coding RNAs: biogenesis, functional diversity, and disease associations of circRNAs and tinyRNAs.Molecular biology reports · 2025Review
- The Role of Non-Coding Regions in Breast Cancer: From Gene Regulation to Therapeutic Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Mechanistic insights into circularization viaMolecular therapy. Nucleic acids · 2025Article
- Development and comprehensive evaluation of scarless circularization systems for circular RNA therapeutics.Molecular therapy. Nucleic acids · 2025Article
- Circular RNAs in hepatitis B virus-induced hepatocellular carcinoma: A comprehensive review and recent advances.Genes & diseases · 2025Review
- CircRNAs: functions and emerging roles in cancer and immunotherapy.BMC medicine · 2025Review
- Self-splicing RNA circularization facilitated by intact group I and II introns.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNA (circRNA) has various advantages over linear mRNA that is gaining success as a new vaccine and therapeutic agent. Thus, circRNA and its engineering methods have attracted attention recently. In this study, we developed a new
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.